Nanoparticle-Drug Conjugates Against Resistant Cancers

  • Author: ChemistryViews.org
  • Published: 23 December 2017
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Nature Communications/Nature Publishing Group
thumbnail image: Nanoparticle-Drug Conjugates Against Resistant Cancers

Advanced ovarian cancer is very difficult to treat, and can be resistant to common platinum-based anticancer drugs. New drugs that are both efficient against this type of cancer and have a limited toxicity are, thus, needed.


Michael J. Birrer, Massachusetts General Hospital and Harvard Medical School, both Boston, MA, USA, P. Peter Ghoroghchian, Koch Institute for Integrative Cancer Research, Cambridge, MA, Dana Farber Cancer Institute and Harvard Medical School, both Boston, MA, USA, and colleagues have developed nanoparticle conjugates of a highly potent anticancer drug that could be used for treating ovarian cancer. The team used a triblock copolymer to create biodegradable nanoparticles and covalently bound the drug monomethyl auristatin E (MMAE) to the particles' surface.


The researchers injected the nanoparticle conjugates into the abdomen of mice carrying xenografts of ovarian cancer. They found that the nanoparticles accumulate in the tumors and release MMAE, which inhibits tumor growth while preventing toxicity to healthy tissue. The conjugates also showed improved activity against resistant tumors compared to platinum-based drugs.


 

Article Views: 783

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH